Healthequity (NASDAQ:HQY)‘s stock had its “buy” rating restated by research analysts at Cantor Fitzgerald in a report issued on Tuesday. They currently have a $56.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 15.49% from the stock’s current price.

A number of other equities research analysts also recently issued reports on HQY. Zacks Investment Research raised shares of Healthequity from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Wednesday, October 11th. BidaskClub downgraded shares of Healthequity from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Oppenheimer reissued a “buy” rating and issued a $61.00 price target on shares of Healthequity in a research note on Wednesday, September 6th. Robert W. Baird reissued a “hold” rating on shares of Healthequity in a research note on Thursday, September 21st. Finally, Chardan Capital boosted their price target on shares of Healthequity from $58.00 to $62.00 and gave the company a “buy” rating in a research note on Wednesday. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Healthequity currently has a consensus rating of “Buy” and a consensus target price of $58.33.

Shares of Healthequity (NASDAQ HQY) traded down $0.37 during midday trading on Tuesday, hitting $48.49. 516,400 shares of the stock traded hands, compared to its average volume of 522,736. Healthequity has a 1-year low of $37.62 and a 1-year high of $55.31. The firm has a market capitalization of $2,955.48, a price-to-earnings ratio of 77.56, a price-to-earnings-growth ratio of 2.14 and a beta of 1.74.

Healthequity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.04. Healthequity had a net margin of 20.27% and a return on equity of 13.93%. The firm had revenue of $56.80 million for the quarter, compared to the consensus estimate of $55.27 million. During the same period last year, the firm posted $0.10 earnings per share. The company’s revenue for the quarter was up 31.0% on a year-over-year basis. analysts predict that Healthequity will post 0.7 earnings per share for the current fiscal year.

In related news, Director Frank Medici sold 316,644 shares of Healthequity stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $51.96, for a total value of $16,452,822.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Berkley Capital, Llc sold 373,500 shares of Healthequity stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $53.21, for a total transaction of $19,873,935.00. The disclosure for this sale can be found here. Insiders sold 1,743,212 shares of company stock valued at $91,145,351 in the last 90 days. Company insiders own 19.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of HQY. Zions Bancorporation acquired a new position in Healthequity during the 3rd quarter worth approximately $119,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Healthequity by 105.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock worth $127,000 after acquiring an additional 1,308 shares in the last quarter. Riverhead Capital Management LLC grew its holdings in Healthequity by 75.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock worth $131,000 after acquiring an additional 1,129 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in Healthequity by 7.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,686 shares of the company’s stock worth $134,000 after acquiring an additional 191 shares in the last quarter. Finally, Fortaleza Asset Management Inc. acquired a new position in Healthequity during the 2nd quarter worth approximately $138,000. Institutional investors own 98.60% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Healthequity’s (HQY) Buy Rating Reaffirmed at Cantor Fitzgerald” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/06/healthequitys-hqy-buy-rating-reaffirmed-at-cantor-fitzgerald.html.

About Healthequity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity Inc and related companies with MarketBeat.com's FREE daily email newsletter.